Why is Abbott Laboratories stock down 1.8% today?

Traders Union
All News
Stocks
Abbott laboratories slides 1.87% today

Highlights

Abbott Laboratories attracted significant institutional inflows in the second quarter, with AXQ Capital LP and VELA Investment Management LLC increasing their stakes.
Abbott Laboratories reported second-quarter revenue of $12.59 billion and earnings per share of $1.31, maintaining 54 years of consecutive dividend increases.
Shares of Abbott Laboratories remain under seller pressure, trading near $106.29, with the five-day range forecast at $103.2 to $108.33 and technical signals showing heavy oversold conditions.

Institutional buying persists as broader selling pressure weighs on shares

Significant institutional investment activity was recorded in Abbott Laboratories, with AXQ Capital LP and VELA Investment Management LLC notably increasing their holdings during the second quarter. The company reported second-quarter revenue of $12.59 billion and earnings per share of $1.31 following its July earnings release. Abbott maintained its reputation for dividend consistency, raising dividends for 54 consecutive years and reporting a payout ratio between 46% and 81.55%. These developments were accompanied by overall price action that has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, points to continued institutional activity in Abbott Laboratories but sees ongoing downward momentum dominating short- and long-term trends. He notes that despite steady earnings and a long dividend history, heavy selling pressure is evident from both technical and sentiment indicators. Kharitonov highlights that the RSI, CCI, and Stochastic RSI all confirm the stock is firmly oversold while the price struggles under major moving averages. He emphasizes that intraday lows may not hold if broader sentiment fails to recover. "Persistent weakness in key technical signals outweighs recent positive news and may lead to further declines if support breaks," he warns.

Viktoras Karapetjanc, expert at Traders Union, emphasizes the strong institutional support for Abbott Laboratories and its robust dividend track record. He sees consistent revenue and active accumulation as positive signs, even during periods of price pressure. Karapetjanc notes that the medium-term technical structure is holding, offering a foundation for renewed gains as sentiment stabilizes. "With institutional inflows and sustained dividend growth, the setup favors buyers once short-term uncertainty clears," he says.

Sholanke Dele, market strategist, believes Abbott Laboratories faces a challenging short-term outlook. He points to volatility and persistent seller control as signs that bulls lack momentum right now. Dele warns that oversold readings do not guarantee an imminent reversal. "Until strong evidence of buying returns, I remain cautious on the short-term direction," he states.

Oversold signals dominate as technical momentum and support diverge

Abbott Laboratories is trading below both its 20-day and 200-day moving averages at $111.89 and $106.3 respectively, but remains above the 50-day moving average at $104.37. This configuration signals persistent short- and long-term pressure from sellers, with medium-term support still present. The near-term ceiling is set by the 200-day moving average at $106.3, and the immediate floor by today’s low of $105.79. Momentum signals are mixed: the MACD indicates strong upward momentum and the ADX suggests active buying interest, but the RSI at 47.26, CCI at -100.34, Stochastic RSI at 0, and BBP at -0.83 all point to heavy oversold conditions and clear intraday seller dominance. The stock opened nearly flat and is trading near its daily low, with volatility amplitude at 2.42%. The intraday tone is pressured, reflecting the oversold signals detected by technical oscillators.

Earlier, analysts noted that Abbott Laboratories was in a consolidation phase, with mixed technical signals and the potential for near-term volatility. The latest technical and institutional activity corroborates this view, with an actionable focus on whether the stock can sustain support above $105.79 or risk a slide toward the next volatility threshold at $103.2.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.